HC Wainwright Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock

Belite Bio (NASDAQ:BLTE) had its price target lifted by equities research analysts at HC Wainwright from $185.00 to $200.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 13.16% from the stock’s current price.

A number of other brokerages have also weighed in on BLTE. Bank of America started coverage on shares of Belite Bio in a research note on Monday, January 26th. They set a “buy” rating and a $195.00 target price on the stock. Morgan Stanley lifted their price target on shares of Belite Bio from $191.00 to $201.00 and gave the company an “overweight” rating in a report on Tuesday. Mizuho set a $223.00 price target on shares of Belite Bio in a research note on Thursday, February 19th. Maxim Group set a $200.00 price target on Belite Bio in a research report on Tuesday, December 2nd. Finally, Benchmark reissued a “buy” rating on shares of Belite Bio in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $200.50.

Belite Bio Stock Down 0.5%

NASDAQ:BLTE traded down $0.84 during trading hours on Tuesday, hitting $176.74. 165,487 shares of the company traded hands, compared to its average volume of 227,122. The company has a market cap of $6.63 billion, a PE ratio of -92.05 and a beta of -1.46. The firm’s 50-day simple moving average is $168.66 and its 200-day simple moving average is $122.59. Belite Bio has a one year low of $49.00 and a one year high of $200.00.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.18. As a group, equities research analysts expect that Belite Bio will post -1.17 EPS for the current year.

Hedge Funds Weigh In On Belite Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC acquired a new stake in Belite Bio in the 2nd quarter worth approximately $147,000. Marshall Wace LLP purchased a new position in shares of Belite Bio during the 2nd quarter valued at about $547,000. BNP Paribas Financial Markets acquired a new position in Belite Bio in the second quarter valued at approximately $190,000. GAMMA Investing LLC boosted its holdings in Belite Bio by 11.1% during the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after buying an additional 176 shares in the last quarter. Finally, High Net Worth Advisory Group LLC acquired a new stake in shares of Belite Bio during the 3rd quarter valued at about $259,000. 0.53% of the stock is owned by hedge funds and other institutional investors.

Belite Bio News Summary

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $266 and reiterated an “overweight” rating — implying roughly a 52% upside from the referenced price, signaling strong analyst conviction on commercial upside. Cantor Fitzgerald PT Raise
• Positive Sentiment: Morgan Stanley raised its price target to $201 and maintained an “overweight” rating — another institutional upgrade supporting upside expectations. Morgan Stanley PT Raise
• Positive Sentiment: Belite beat Q4 EPS estimates (reported -$0.38 vs. consensus -$0.56), a near-term fundamental beat that reduces near-term execution risk and supports valuation. Earnings Beat / Conference Call
• Positive Sentiment: Management is targeting a Q2 2026 NDA submission for its Stargardt therapy and reports a surge in cash reserves — a clear near-term regulatory milestone and stronger balance-sheet signal that can de-risk commercialization. NDA Timeline & Commercialization Plan
• Neutral Sentiment: Belite released preliminary, unaudited Q4 and full-year 2025 results and a corporate update; details reinforce the company narrative but are largely already priced alongside the formal earnings release. Corporate Update / Preliminary Results
• Neutral Sentiment: Belite will participate in the Leerink Global Healthcare Conference — useful for investor visibility but not an immediate stock mover unless new data or guidance is disclosed. Leerink Conference Participation
• Neutral Sentiment: An earnings call transcript is available for further detail on guidance and commercialization planning; useful for due diligence but not new news. Earnings Call Transcript
• Neutral Sentiment: Reported short-interest data in the feed appears erroneous (shows zero / NaN) and is not a reliable indicator of current short pressure. No clear short-interest catalyst from that report.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.